Related Experiment Video
Updated: Apr 21, 2026
Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography
Published on: July 10, 2018
Anti-inflammatory effects of 3PO in asthmatic airway inflammation: an integrated study using network pharmacology,
Siqing Huang1,2, Shuna Wei2,3, Fang Luo4
1The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.
Introduction:
Recent studies have highlighted the critical role of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) in inflammation, with inhibitors like 3PO showing therapeutic potential in various inflammatory diseases. However, its effect on asthma inflammation remains unclear.
Methods:
Our study employed an integrative strategy-combining network pharmacology, molecular docking, molecular dynamics simulations, and in vivo experiments-to investigate 3PO's anti-inflammatory action in asthma.
Results:
Firstly, the construction of a protein-protein interaction (PPI) network identified nine hub genes: TNF, IL6, BCL2, IL1B, CASP3, RELA, MAPT, MAOB, and MAOA. Then, the KEGG pathway enrichment analysis identified the nuclear factor kappa B (NF-κB) pathway as a pivotal target. Molecular docking and dynamics simulations suggested stable interactions between 3PO and key inflammatory markers, including tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and NF-κB P65. For experimental validation, the OVA-induced asthma mouse models were established. PFKFB3 expression was markedly upregulated in the lung tissues of asthmatic mice. 3PO treatment modulated mediator levels in BALF of asthmatic mice by reducing interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-13 (IL-13), interleukin-17A (IL-17A), IL-1β, TNF-α, IL-6, lactate, Immunoglobulin E (IgE), and chemokine (C-C motif) ligand 11 (CCL11), while elevating interleukin-10 (IL-10). 3PO treatment alleviated hallmark features of asthma in this model, such as airway mucus hypersecretion, goblet cell hyperplasia, and peribronchial infiltration of inflammatory cells, particularly eosinophils. Furthermore, 3PO treatment reversed key protein changes in lung tissue by increasing inhibitor of nuclear factor Kappa B-α(IKB-α) and decreasing p-NF-κB P65.
Discussion:
These results indicate that 3PO exerts anti-inflammatory effects in asthma, and this process is associated with the suppression of the NF-κB pathway, providing a novel therapeutic rationale for asthma therapy.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
01:13Asthma III: Clinical Manifestations
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.